Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular or Subcutaneous Route in Participants Aged 65 Years and Older in Japan

NCT03233217 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.

NCT NCT03233217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03233217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular or Subcutaneous Route in Participants Aged 65 Years and Older in Japan
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Phase
Phase 1/2
Overall status
Completed
Start date
September 15, 2017
Completion date
November 28, 2017
Enrollment
175 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

influenza